Welcome to our dedicated page for CVS Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on CVS Health stock.
CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
CVS Health (NYSE: CVS) reported expanding community health investments across Massachusetts, focused on affordable housing, nonprofit partnerships and free health services. According to CVS Health, the company has invested more than $83 million in affordable housing, helping create, preserve or renovate over 3,517 affordable units in cities including Worcester, Boston’s Jamaica Plain, Salem, Attleboro and Foxborough.
Recent projects include a $10 million investment in the former Worcester Boys Club, creating 80 affordable units for older adults, and over $16 million for transforming Blessed Sacrament in Jamaica Plain into 55 affordable family homes and a community arts and youth space. CVS Health also supports medically tailored meals through Community Servings and funds preventive care via Project Health® screenings and the DREAMH postpartum mobile care program with Mass General Brigham.
CVS Health (NYSE: CVS) announced that common prescription medications for dogs and cats are now available at approximately 9,000 CVS Pharmacy locations nationwide as of July 21, 2026. Pet owners can fill select pet-only prescriptions, such as antibiotics, allergy treatments, flea and tick control, insulin, and pain relievers, at local CVS Pharmacy stores, with options for in-store pickup or delivery where eligible.
According to CVS Health, pet prescriptions can use many of the same pharmacy services as human prescriptions, including automatic refills and prescription syncing, and can be managed via CVS.com profiles and the CVS Health app. The company also highlighted its in-store and online Pet section, including its Pet Central brand and national pet product brands.
CVS Health (NYSE: CVS) announced the opening of its first pharmacy-focused CVS Pharmacy location in Houston, at 8503A Gulf Freeway, as part of a plan to open nearly 20 such sites nationwide. These neighborhood pharmacies, averaging about 3,000 square feet, feature full-service prescription dispensing and a curated range of over-the-counter products.
According to CVS Health, the new format is designed to expand access to in-person pharmacy care, complementing existing traditional stores, store-in-store pharmacies, MinuteClinic locations, and Oak Street Health co-located centers. The company has already opened pharmacy-focused sites in Birmingham, Chicago, Detroit, and Washington, D.C., and plans two more in greater Houston plus over 40 additional CVS Pharmacy locations, including traditional stores and pharmacies in Target. CVS highlights survey data showing 80% of patients prefer face-to-face pharmacy care and 97% of pharmacy professionals view in-person interactions as vital.
Aetna, a CVS Health company (NYSE: CVS), released results from its Q2 2026 Aetna Provider Survey, a quarterly study of 723 U.S. providers conducted by Morning Consult. The average provider-payer trust score rose to 6.1 on a 1–10 scale, up from 5.4 in Q1, with 38% rating payers 8 or higher.
According to Aetna, providers report improving views of payers: 52% say payers deliver on promises (+16 percentage points vs Q1), 56% see clear coverage information (+12 points), and 44% say payers help patients navigate care (+6 points). Administrative burden remains the top challenge, with 84% citing managing patient records or prior authorization. Providers identify prior authorization submission (58%), re-entering patient data (42%) and claims submission (41%) as key areas for technology support, with over 30% expecting to save more than an hour daily and 80% expecting to save over 30 minutes.
Interoperability and data integrity are the leading technology challenges for 68% of providers, and 29% view real-time patient data as the most important action payers can take. Nearly half (47%) think such data could save more than 10 minutes per appointment, enabling more informed point-of-care decisions (63%), fewer claim denials/resubmissions (54%) and reduced wait times for treatment approvals (47%). Providers also see value in payer digital tools: 71% agree they help patients understand benefits and care options, 68% say they clarify prior authorization status, and 72% say they improve claims status transparency. Looking ahead five years, 84% of respondents expect technology advances to improve health outcomes and 72% expect both population health and patient experience to improve.
CVS (NYSE: CVS), through CVS Caremark, announced a global settlement with the Federal Trade Commission that resolves all outstanding FTC litigation and investigations involving its pharmacy benefit management and affiliated pharmacy businesses, including rebate, pharmacy network contracting, and vertical integration issues.
According to CVS Caremark, the agreement removes ongoing legal overhang and formalizes a series of changes aimed at affordability and transparency, such as aligning member cost sharing with net drug costs, moving away from rebate guarantees and spread pricing, and expanding detailed reporting on drug prices, rebates, and member payments.
CVS Caremark reported negotiating nearly $80 billion in client and member prescription savings last year, delivering nearly $900 million in point-of-sale rebates to 25 million Americans, and expects clients to drive about $450 million in annual savings over each of the next 10 years through expanded point-of-sale rebate adoption and related innovations.
CVS Health (NYSE: CVS) announced that its board of directors has approved a quarterly cash dividend of $0.665 per share on its common stock. The dividend will be paid on August 3, 2026, to shareholders of record as of July 23, 2026.
CVS Health (NYSE: CVS) will hold its second quarter 2026 earnings conference call with analysts and investors on Wednesday, August 5, 2026, at 8:00 a.m. ET.
An audio webcast will be available live and archived for one year at investors.cvshealth.com.
CVS (CVS), through the CVS Health Foundation, is investing $1 million via its Hometown Fund in 20 Rhode Island nonprofits.
Grants support access to health care, food, stable housing and essential services, and follow more than $2.64 million in 2025 charitable giving and other community investments in Rhode Island.
CVS (NYSE:CVS), through the CVS Health Foundation, is awarding $1 million in Hometown Fund grants to 20 nonprofits in Greater Hartford. Funding targets access to health care, food security, stable housing and essential community services.
In 2025, CVS Health and its foundation contributed $2.61 million in charitable giving across Connecticut.
CVS (NYSE: CVS) announced expanded GLP‑1 support across more than 9,000 CVS Pharmacy locations and MinuteClinic virtual care nationwide. The initiative combines lower-cost access, pharmacist guidance, and over-the-counter products to help patients start and stay on GLP‑1 therapy.
Key elements include CVS participation in the CMS Medicare GLP‑1 Bridge program from July 1, 2026, through December 31, 2027, offering eligible Medicare patients select GLP‑1 medications for $50 monthly copays. For commercially insured patients, out-of-pocket costs can be as low as $25 per month with manufacturer coupons, or $149 per month for certain uninsured patients using manufacturer vouchers.
MinuteClinic is launching a new virtual weight management program with $49 self-pay visits, available in 47 states and Washington, D.C., for adults ages 18‑64. Licensed clinicians can assess metabolic health and, when clinically appropriate, prescribe FDA-approved GLP‑1 medications for weight loss with follow-up support.